Pattern of drug resistant Mycobacterium tuberculosis in the west and northwest of Iran: a meta-analysis
Abstract
Background and Objectives: Drug-resistant tuberculosis (Tb) is a major public health issue across the world. Therefore, it is crucial to determine its pattern in different regions of the world. The aim of this study was to review the prevalence of drug resistant TB in the west and northwest of Iran.
Materials and Methods: A systematic literature search was performed to identify studies (2010 to 2021) in Google Scholar, PubMed, Thomson Reuters, Scientific Information Database (SID), Cochrane Library, and Medical Library (MedLib) databases. The patterns of any drug-resistant Mycobacterium tuberculosis (MTB); resistance to isoniazid (INH), rifampicin (RMP), streptomycin (SMP), ethambutol (EMB), and multiple drug resistance (MDR) were reviewed in tuberculosis in the west and northwest of Iran.
Results: In this review, 7 studies met the eligibility criteria for a meta-analysis. The pooled proportion of any drug resistant TB was 13% (CI 95%: 9.0, 17.0) (43.0% in re-treatment group). The pooled prevalence of any drug resistant TB was more than 1.5 times higher in men compared to women (15% vs. 9.0%). The pooled prevalence (%) of resistance to INH, RMP, SMP, EMB and MDR-TB was 11.0%, 12.0%, 13.0%, 6.0%, and 6.0%, respectively. Kermanshah Province (a province in the west of Iran) showed a high prevalence of any type of drug resistance and MDR-TB (15.9% and 20.0%, respectively).
Conclusion: It seems that the western provinces of Iran have a different pattern of drug resistance compared to the northwestern provinces. Considering the extent of Iran and the neighboring countries, it is recommended that the pattern of tuberculosis drug resistance be reviewed separately in different provinces or regions of Iran. Drug resistance in the re-treatment group was more than three times that of all patients with TB drug resistance. The burden of drug resistance reduces significantly with better control and management of TB drug treatment and preventing re-infection.
2. Eurosurveillance editorial team. WHO publishes Global tuberculosis report 2013. Euro Surveill 2013; 18: 20615.
3. Nasiri MJ, Dabiri H, Darban-Sarokhalil D, Rezadehbashi M, Zamani S. Prevalence of drug-resistant tuberculosis in Iran: systematic review and meta-analysis. Am J Infect Control 2014; 42: 1212-1218.
4. Sahebi L, Ansarin K, Hoffner S, Mohajeri P, Mohammadi A. Beijing strains of Mycobacterium tuberculosis in smear-positive tuberculosis patients in North-West and West of Iran. Adv Biomed Res 2016; 5: 181.
5. Nasiri MJ, Rezaei F, Zamani S, Darban-Sarokhalil D, Fooladi AA, Shojaei H, et al. Drug resistance pattern of Mycobacterium tuberculosis isolates from patients of five provinces of Iran. Asian Pac J Trop Med 2014; 7: 193-196.
6. Sahebi L, Ansarin K, Mohajeri P, Khalili M, Monfaredan A, Farajnia S, et al. Patterns of drug resistance among Tuberculosis patients in West and Northwestern Iran. Open Respir Med J 2016; 10: 29-35.
7. Mohajeri P, Norozi B, Atashi S, Farahani A. Anti Tuberculosis drug resistance in west of Iran. J Glob Infect Dis 2014; 6: 114-117.
8. Heidarnejad H, Nagili B. Primary resistance of Mycobacterium tuberculosis to isoniazid, streptomycin, rifampin, and ethambutol in pulmonary tuberculosis. Arc Iran Med 2001; 4: 1-4.
9. Dooley KE, Lahlou O, Ghali I, Knudsen J, Elmessaoudi MD, Cherkaoui I, et al. Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco. BMC Public Health 2011; 11: 140.
10. Sahebi L, Ansarin K, Maryam S, Monfaredan A, Sabbgh Jadid H. The factors associated with tuberculosis recurrence in the northwest and west of Iran. Malays J Med Sci 2014; 21: 27-35.
| Files | ||
| Issue | Vol 14 No 3 (2022) | |
| Section | Meta-analysis | |
| DOI | https://doi.org/10.18502/ijm.v14i3.9754 | |
| Keywords | ||
| Drug resistance; Tuberculosis; Meta-analysis | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
